The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.

Abstract

Levodopa is the most efficacious treatment for Parkinson's disease (PD). Long-term treatment with levodopa is limited due to dyskinesia. Dyskinesia in PD can be socially and functionally disabling. Extended-release amantadine (amantadine ER) is the first approved medication for the treatment of dyskinesia. When it is given at bedtime, it reaches plasma concentration approximately twice the level achieved by amantadine immediate release. Amantadine ER reduces the severity and duration of dyskinesia during the day, reduces OFF time and increases ON time without troublesome dyskinesia. The most common side effects are hallucination, dizziness, orthostatic hypotension and pedal edema. This review discusses the safety and efficacy of amantadine ER in dyskinesia in PD patients.

• Authors: Mazen T Elkurd, Laxman B Bahroo, Rajesh Pahwa
• Journal: Neurodegenerative disease management (Neurodegener Dis Manag) Vol. 8 Issue 2 Pg. 73-80 (04 2018) ISSN: 1758-2032 [Electronic] England
• PMID: 29564954 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Analgesics, Non-Narcotic
• Antiparkinson Agents
• Levodopa
• Amantadine

Topics

• Amantadine (therapeutic use)
• Analgesics, Non-Narcotic (therapeutic use)
• Antiparkinson Agents (adverse effects)
• Drug Delivery Systems
• Dyskinesia, Drug-Induced (drug therapy)
• Humans
• Levodopa (adverse effects)
• Parkinson Disease (drug therapy)